Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue | $23.6M | $228.5M | $329.3M | $366.7M | $410.5M | $425.0M |
| Cost of revenue | $12.0M | $25.7M | $35.4M | $33.4M | $32.0M | $31.0M |
| Gross profit | $11.6M | $202.9M | $293.9M | $333.3M | $378.4M | $393.9M |
| Gross margin | 49.1% | 88.8% | 89.3% | 90.9% | 92.2% | 92.7% |
| R&D | $0 | $0 | $0 | $0 | $467.6K | $0 |
| Operating income | −$2.2M | $17.3M | −$41.8M | −$90.4M | $128.7M | −$3.1M |
| EBITDA | $4.1M | $58.2M | $21.2M | −$10.3M | $227.9M | $56.1M |
| Net income | −$4.1M | −$9.2M | −$86.6M | −$131.6M | $104.3M | −$59.3M |
| Net margin | -17.5% | -4.0% | -26.3% | -35.9% | 25.4% | -14.0% |
| EPS (diluted) | -0.20 | -0.44 | -4.13 | -6.29 | 5.11 | -2.94 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $459M | $1.96 | $1.96–$1.96 | 1 |
| 2027 | $503M | $2.06 | $2.06–$2.06 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds CSAMF.
No tracked institution reports a position in CSAMF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2024-04-29 | $0.4769 | 2024-05-10 |
No one on the platform has traded CSAMF yet.
| $123M |
| — |
| EPRXFEupraxia Pharmaceuticals Inc. | $3.04 | -6.17% | $108M | — |
| HITCHealthcare Integrated Technologies, Inc. | $0.29 | +0.00% | $53M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.